研報掘金丨國泰君安:首予聯影醫療“增持”評級,目標價156.55元
國泰君安研報指出,聯影醫療(688271.SH)是一家快速崛起的醫療影像設備國產龍頭企業,憑藉業內領先的創新產品和解決方案,國內市場份額已比肩國際巨頭,海外市場亦逐步打開,公司海外業務仍有巨大提升空間,未來數年內有望保持高速增長,爲業績增長貢獻強勁動能。在國內公司已入駐全國超1000家三甲醫院,針對不同等級的醫院推出差異化的創新產品和解決方案,得到臨牀廣泛認可,在多個細分產品線的市場份額已達到行業第一或領先地位。2024年受到招標延期影響國內業務承壓,2025年起隨着大規模設備更新政策全面落地,有望充分把握政策利好帶來的機遇,國內業務有望實現強勁復甦。參考可比公司估值,給予2025年目標PE 71X,對應目標價156.55元,首次覆蓋,給予“增持”評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.